Search results
Results from the WOW.Com Content Network
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In this article we will take a look at the 15 most valuable biotech companies in the world. You can skip our detailed analysis of the biotechnology industry’s outlook for 2021, and some of the ...
On top of these dilutive security offerings, there are no guarantees that the research undertaken by these biotech companies will bear fruit. In fact, only around 10% of experimental drugs manage ...
This list comprises the largest companies currently in the United States by revenue as of 2024, according to the Fortune 500 tally of companies and Forbes. The Fortune 500 list of companies includes only publicly traded companies, also including tax inversion companies. There are also corporations having foundation in the United States, such as ...
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
BioMarin has recently had a string of good news resulting in the company upgrading its full-year revenue predictions. The $17.25 billion company specializes in pioneering treatments for rare ...